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Abstract: Lactoferrin (LF) exhibits a wide range of immunomodulatory activities including
modulation of cytokine and chemokine secretion. In this study, we demonstrate that bovine LF
(bLF) up-modulates, in a concentration- and time-dependent manner, CCL1 secretion in monocytes
(Mo) at the early stage of differentiation toward dendritic cells (DCs), and in fully differentiated
immature Mo-derived DCs (MoDCs). In both cell types, up-modulation of CCL1 secretion is an early
event following bLF-mediated enhanced accumulation of CCL1 transcripts. Notably, bLF-mediated
up-regulation of CCL1 involves the engagement of distinct surface receptors in MoDCs and
their Mo precursors. We show that bLF-mediated engagement of CD36 contributes to CCL1
induction in differentiating Mo. Conversely, toll-like receptor (TLR)2 blocking markedly reduces
bLF-induced CCL1 production in MoDCs. These findings add further evidence for cell-specific
differential responses elicited by bLF through the engagement of distinct TLRs and surface receptors.
Furthermore, the different responses observed at early and late stages of Mo differentiation towards
DCs may be relevant in mediating bLF effects in specific body districts, where these cell types may
be differently represented in physiopathological conditions.
Keywords: monocyte; dendritic cell; lactoferrin; CCL1; surface receptors
1. Introduction
Lactoferrin (LF) is an iron binding glycoprotein belonging to the transferrin family that is
considered a major component of the mammal’s innate immune system. LF is found primarily in
mucosal secretions, synthesized by epithelial cells, but also stored in specific neutrophilic granules [1].
LF is a first-line defense protein involved in protection against a multitude of microbial infections
and prevention of systemic inflammation, thus helping the host to fight against microbes but also
protecting it against the harmful effects of inflammation [2–4]. Although the role of LF in maintaining
immune system homeostasis has not been fully elucidated, some regulatory activity may depend on
its interaction with pathogen-associated molecular patterns and other surface receptors expressed on
innate cells including monocytes (Mo), macrophages and dendritic cells (DCs) [5,6].
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The mononuclear phagocyte system is a body-wide network of specialized cells such as
macrophages and DCs, that play distinct and complementary immunological roles and overall
contribute to tissue homeostasis, inflammation, and immune defense [7]. Mo continuously migrate
from the blood into peripheral tissues where, in response to environmental stimuli, they differentiate
into DCs [8]. These latter cells are the most potent and versatile antigen-presenting cells (APCs)
capable of inducing protective adaptive immune responses and tolerance to self-antigens. In response
to a variety of microbial and endogenous stimuli, resting DCs undergo a maturation process and
migrate to the lymph node where they activate the adaptive immune response [9].
Chemokines control leukocyte migration and fulfill essential functions in homeostatic and
inflammatory immune processes. CC chemokine ligand 1 (CCL1) is a CC chemokine mainly secreted
by immune cells (e.g., Mo, activated macrophages and T cells, DCs and mast cells), dermal blood
vasculature, and by melanocytes and Langerhans cells in the skin [10–12]. Human CCL1 interacts
uniquely with the CC chemokine receptor 8 (CCR8). Early data on the expression of this receptor
pointed to CCR8 being expressed by a number of T cell subsets, including Th1, Th2, T regulatory
(Treg) cells, and thymocytes with natural Treg function, whereas expression and function of CCR8
in monocytes, DCs, and NK cells is still controversial [12,13]. The main function of the CCL1
interaction with CCR8 is the steady-state homing regulation of long-lived lymphocyte populations
to skin tissue [10,14,15]. Nowadays, the CCL1/CCR8 axis is one of the least understood chemokine
systems in spite of the fact that CCL1 was the first among a long succession of CC chemokines
to be discovered [16,17]. Several functions have been attributed to CCL1 including the regulation
of Treg and Th2 cells, as well as DC trafficking [10,18,19], IFN-γ production by CD8+ T cells [20],
and allergic mucosal inflammation [10,21]. Inflammatory cytokines (i.e., TNF-α and IL-1β) are known
to induce CCL1 expression from cultured dermal endothelium [10]. DCs and their Mo precursors
express moderate to large amounts of CCL1 mRNA upon activation with bacterial lipopolysaccharide
(LPS) or peptidoglycan [10]. In addition, IL-4, IL-13, and IFN-γ can enhance CCL1 production
from bronchial epithelial cells [22]. Lastly, in human Mo, CCL1 is induced by costimulation with
FcγRII engagement and IL-1 or LPS [23,24], as well as by toll-like receptor (TLR)3, TLR4 and TLR8
ligands [25].
In this study, we report that bovine LF (bLF) up-modulates CCL1 expression in Mo-derived
DCs (MoDCs) and their Mo precursors by distinct mechanisms involving the trans-membrane
glycoprotein TLR2 and CD36. Overall, these cell-specific bLF-mediated effects may represent a
strategy to elicit anti-inflammatory responses in specific body districts, where these cell types may
be differently represented in physiopathological conditions.
2. Results
2.1. bLF Up-Modulates CCL1 Expression in Mo and MoDCs
To get insights into bLF capacity to modulate cytokine/chemokine expression during the course
of DC differentiation, Mo induced to differentiate toward DCs were treated with bLF at day 0 (Mo)
or at day 5 (MoDCs) of culture and supernatants collected after 18 h. We found that Mo respond to
bLF by up-modulating CCL1 secretion over basal levels. As shown in Figure 1A, bLF exposure of Mo
soon after seeding influences CCL1 production in a concentration-dependent manner. Although no
differences in the production of this chemokine were observed upon addition of 1 µg/mL of bLF with
respect to the untreated control culture, CCL1 secretion was already observed with 10 µg/mL (3.3 fold
increase versus control; p < 0.01; n = 6), and further increased at the concentration of 100 µg/mL of
bLF (5.6 fold increase versus control; p < 0.01; n = 6). Low levels of CCL1 secretion were already
detected at 8 h after bLF treatment but strongly increased at 18 h (Figure 1B). In addition, CCL1
was still detected in the culture supernatant at the end of the culture period (six days), when Mo
treated with bLF have fully differentiated into MoDCs, even upon medium replacement 18 h post
bLF treatment (Figure 1C), thus indicating that CCL1 secretion is not a transient event but continues
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in spite of stimulus removal. We have previously demonstrated that freshly isolated Mo, but not
MoDCs, respond to bLF by secreting IL-6 [26]. Thus, we comparatively assessed the effect of a single
treatment with bLF (100 µg/mL) in day 0 Mo or fully differentiated day 5 MoDCs on the production
of this chemokine. As shown in Figure 1D, in spite of a clear-cut variability among donors in term of
basal levels of CCL1 release and extent of response, bLF significantly up-modulated CCL1 secretion
in both cell types. However, chemokine production was significantly higher in cultures stimulated at
day 0 (Mo) with respect to those treated at day 5 (MoDCs).
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treated with  100  μg/mL  of  bLF  or  left  untreated  for  18  h  (0  to  18  h),  then  culture medium was 
replaced with fresh medium containing GM‐CSF/IL‐4 and cells were cultured for an additional five 
days  (18 h  to Day  6).  Some  cultures were  treated with bLF  soon  after  seeding,  concomitantly  to 
GM‐CSF/IL‐4, and culture supernatants were collected after six days  (0  to Day 6). Data  from  four 
independent  donors  are  shown.  (D) Dot  plot  of CCL1  content  in  cell  supernatants  from Mo  or 
MoDCs obtained from 20 independent donors. Cells were treated with 100 μg/mL bLF for 18 h or left 
untreated. Means ± SEM are indicated. (A) p values obtained by 1‐way ANOVA (overall p < 0.0001) 
are  shown.  (B–D)  p  values  obtained  by  Student  t  test  for  paired  samples  are  shown.  *  p  ≤  0.05,   
** p ≤ 0.01, *** p ≤ 0.001. 
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Figure 1. bLF-induced CCL1 secretion in Mo and MoDCs. Freshly isolated Mo were stimulated
to differentiate to MoDCs in the presence of GM-CSF/IL4 and concomitantly treated with bLF
or left untreated (none). (A) CCL1 content in culture supernatants of Mo stimulated with
different concentrations of bLF for 18 h. Means ˘ SEM from six independent donors are shown;
(B) Time-course analysis of CCL1 secretion. Mo were treated with 100 µg/mL of bLF for the indicated
times or left untreated (none). Means ˘ SEM from eight (4 h), four (8 h) and 10 (18 h) independent
experiments are shown; (C) Mo were stimulated to differentiate in the presence of GM-CSF/IL-4 and
concomitantly treated with 100 µg/mL of bLF or left untreated for 18 h (0 to 18 h), then culture
medium was replaced with fresh medium containing GM-CSF/IL-4 and cells were cultured for an
additional five days (18 h to Day 6). Some cultures were treated with bLF soon after seeding,
concomitantly to GM-CSF/IL-4, and culture supernatants were collected after six days (0 to Day 6).
Data from four independent donors are shown; (D) Dot plot of CCL1 content in cell supernatants
from Mo or MoDCs obtained from 20 independent donors. Cells were treated with 100 µg/mL bLF
for 18 h or left untreated. Means ˘ SEM are indicated; (A) p values obtained by 1-way ANOVA
(overall p < 0.0001) are shown; (B–D) p values obtained by Student t test for paired samples are shown.
* p ď 0.05, ** p ď 0.01, *** p ď 0.001.
To further establish whether bLF-stimulated CCL1 production was associated with an increased
accumulation of the corresponding mRNA, RT-PCR experiments were performed at early time points
after bLF treatment. As shown in Figure 2A, in day 0 Mo, bLF significantly enhanced CCL1 mRNA
expression already at 2 h and more markedly at 4 h post-treatment. Although MoDCs exposed to bLF
showed a trend towards a higher accumulation of CCL1 mRNA at both time points assessed (4.6 and
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in  Mo  and  MoDCs,  the  effect  of  neutralizing  antibodies  specific  for  TLR4,  TLR2  and  their 
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Figure 2. CCL1 mRNA accumulation in bLF-exposed Mo and MoDCs. CCL1 mRNA expression was
analyzed by quantitative PCR and expressed as 2´∆∆CT values. Actin was used as reference gene, and
the untreated sample as calibrator. Data are expressed as mean ˘ SE of the fold changes (FC) with
respect to untreated cells from seven (A, o) and four (B, oDC) independent experiments. p values
obtained by Student t test for paired sa ples are sho n. * p ď 0.05.
2.2. bLF-Mediated Up-Modulation of CCL1 Secretion Requires Different Receptors in Mo and MoDCs
LF can interact, specifically or by virtue of its highly cationic nature, with a variety of
cell determinants with different grade of specificity, including molecules involved in pathogen
recognition such as DC-SIGN, CD14, TLR2 and TLR4 [4,5,27]. In this regard, we have previously
demonstrated that engagement of TLR2, CD14 and, to a lesser extent, of TLR4 accounts for
bLF-induced expression of IL-6 in Mo. Furthermore, we reported that cell-specific differences in bLF
internalization likely account for the distinct response elicited by bLF in Mo versus MoDCs [26]. With
the purpose of further investigating the mechanisms through which bLF promotes CCL1 expression
in Mo and MoDCs, the effect of neutralizing antibodies specific for TLR4, TLR2 and their co-receptors
CD14 and CD36 was evaluated. As shown in Figure 3, blocking CD36 significantly reduced the
bLF-mediated CCL1 production in Mo (panel A) but not in MoDCs (panel B). Furthermore, significant
inhibition of CCL1 release was not observed in both cell types upon blocking TLR4 or CD14 (Figure 3,
panels A and B). Surprisingly, neutralization of TLR2 significantly enhanced the bLF-induced CCL1
release in Mo (Figure 3A), whereas it markedly inhibited the production of this chemokine in MoDCs
(Figure 3B). To unravel possible correlations between the degree of receptor expression and CCL1
induction, the surface expression of CD36 and TLR2, and of CD14 and TLR4 as controls, was analyzed
in Mo and MoDCs. As shown in Figure 3C, both cell types expressed TLR2 and CD36, although at
different extent, while TLR4 expression was detected in Mo and barely in MoDCs. As expected,
Mo but not MoDCs exhibited CD14 expression. CD36 has not been recognized yet as a receptor for
LF although evidence for CD36-LF interaction has been previously provided [28]. Thus, to further
investigate the role of CD36 in mediating bLF-induced activities in Mo, the effect of bLF exposure
on the surface expression of this receptor was investigated. As shown in Figure 3D, treatment of Mo
with bLF for 18 h resulted in a marked decrease of CD36 surface expression (from >60% to <30%),
which suggests that receptor internalization occurs upon bLF engagement.
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analyzed  for  CCL1  content  by  ELISA. Mean  ±  SEM  from  11  (Mo)  or  14  (MoDCs)  independent 
experiments  are  shown.  Statistical  significance  of  the  comparison  between  bLF  stimulated  cells 
pretreated with  neutralizing Ab  versus  cells  treated with  control  IgG  isotype was  calculated  by 
one‐way ANOVA  (overall  p  <  0.0001).  (C)  Flow  cytometry  analysis  of  surface  expression  of  the 
indicated  receptors. Solid histograms  represent  control  isotype; dotted  lines  the  specific Ab. Data 
from one donor representative of  four analyzed are shown.  (D) Flow cytometry analysis of CD36 
surface expression upon  treatment of Mo with bLF  (100 μg/mL)  for 18 h. The percentage of CD36 
positive  cells  is  shown. Mean  ±  SEM  from  nine  independent  experiments  are  shown.  p  values 
obtained by Student t test for paired samples are shown. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
3. Discussion 





well as of effector cytokines can be profoundly affected by LF either  to  increase or decrease  their 
production, depending upon the type of  insult recognized by the  immune system  in concert with 
local environmental conditions [4–6]. 
In  this  study, we  report  for  the  first  time  that bLF exposure of Mo and MoDCs  results  in a 
marked  increase  of CCL1  secretion.  This  effect  appears  to  be  significantly  stronger  in Mo with 
respect to MoDCs. Monocytes’ differentiation toward macrophages has been previously associated 
with a different capacity  to  spontaneously produce chemokines as well as  to  respond  to external 
stimuli that modulate their secretion. In this regard, we have previously shown that CCL2 and CCL4 
are constitutively expressed at high  levels  in human peripheral blood Mo, and their expression  is 
further  up‐modulated  during  their  differentiation  into  macrophages  [29,30].  Likewise,  CCL22 
expression is first detected in Mo and reaches maximum levels in fully matured macrophages [31]. 
Differentiation of Mo toward macrophages also modulates the capacity to produce CC chemokine 
Figure 3. bLF up-modulation of CCL1 secretion requires different receptors in Mo and MoDCs.
Mo (A) and MoDCs (B) were pretreated for 30 min with 5 µg/mL of the indicated mAbs, or left
u treated (none), and then stimulated with bLF (100 µg/mL) for 18 h. Culture supernatants
were collected and analyzed for CCL1 co tent by ELISA. Mean ˘ SEM from 11 (Mo) or 14
(MoDCs) indep ndent experiments are shown. Statistical significance of the comparison between
bLF stimulated cells pretreated with neutralizing Ab versus cells treated with control IgG isotype was
calculated by one-way ANOVA (overall p < 0.0001); (C) Flow cytometry analysis of surface expression
of the in icat d receptors. Solid histogram represent control isotyp ; dotted lines the specific Ab.
Data from one donor r presentative of four analyzed are shown; (D) Fl w cytometry analysis of
CD36 surface expressi upon treatment of Mo with bLF (100 µg/mL) for 18 h. The percentage of
CD36 positive cells is shown. Mean ˘ SEM from nine independent experiments are shown. p values
obtained by St t t t . * ď 0.05, ** p ď .01, *** p ď .001.
3. isc ssi
LF is nowadays recognized as a first-line defense protein that plays a critical role in the regulation
of immune response to infectious assault, trauma and injury, naturally bridging innate to adaptive
immune functions. Although the mechanisms underlying the immuno odulatory effects of LF
have not been fully elucidated, its capacity to modulate cytokine/chemokine production has been
shown to contribute importantly to this function. The secretion of pro-inflammatory factors as
well as of effector cytokines can be profoundly affected by LF either to increase or decrease their
production, depending upon the type of insult recognized by the immune system in concert with
local environmental conditions [4–6].
In this study, we report for the first time that bLF exposure of Mo and MoDCs results in a
marked increase of CCL1 secretion. This effect appears to be significantly stronger in Mo with respect
to MoDCs. Monocytes’ differentiation toward macrophages has been previously associated with a
different capacity to spontaneously produce chemokines as well as to respond to external stimuli
that modulate their secretion. In this regard, we have previously shown that CCL2 and CCL4 are
constitutively expressed at high levels in human peripheral blood Mo, and their expression is further
up-modulated during their differentiation into macrophages [29,30]. Likewise, CCL22 expression is
first detected in Mo and reaches maximum levels in fully matured macrophages [31]. Differentiation
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of Mo toward macrophages also modulates the capacity to produce CC chemokine (i.e., CCL2, CCL3,
CCL4) in response to IFN-β [30] as well as to produce CCL1 in response to TLR engagement [25].
Conversely, little information is available on the influence of Mo differentiation toward DCs on the
expression of chemokines. In this study, we show that MoDCs respond less to bLF, with respect to Mo,
as lower levels of CCL1 are found upon induction. In keeping with this observation, we previously
reported that Mo differentiation to MoDCs negatively correlates with the capacity to produce IL-6
in response to bLF [26]. In contrast to the transient onset of IL-6 production, CCL1 was found
to be continuously produced during the course of differentiation as a consequence of the initial
bLF stimulation at the stage of Mo. Overall, these observations suggest the existence of a certain
degree of specificity in the bLF-mediated cytokine/chemokine induction, at least in part related to the
differentiation stage, that may be relevant for the exploitation of LF function in specific body districts.
Herein, we also report that bLF-induced secretion of CCL1 is preceded by enhanced
accumulation of CCL1 mRNA over the basal levels expressed by Mo and MoDCs. Although a
clear-cut increase of this transcript was observed in both cell types upon bLF treatment, statistical
significance was achieved in Mo but not in MoDCs, likely reflecting their lower capacity to secrete
CCL1 in response to bLF (Figure 1D). The increased accumulation of CCL1 transcripts may be either
due to an enhancement of the basal level of transcription or to a stabilization of CCL1 mRNA,
both of which would result in the accumulation of this transcript. LF is known to be internalized
and translocated into the nucleus in some cell types including Mo, where it may regulate the
expression of target genes [26,32,33]. Furthermore, previous reports have documented that LF and its
isoform delta-LF, regulate a number of genes via activation of signaling pathways or via binding to
DNA [34,35]. Although further experiments are needed to precisely define the mechanism of action
of bLF in the regulation of CCL1 mRNA expression, it cannot be ruled out that the more robust
accumulation of CCL1 mRNA in Mo may rely on internalization and nuclear localization of bLF
occurring in Mo but not in MoDCs.
In this study, we also report that bLF engages different receptors to trigger CCL1 secretion in
Mo and MoDCs. Due to its cationic nature, LF binds with a different grade of specificity a variety of
cellular determinants, including bacterial components, strongly anionic molecules, CD14, pathogen
recognition receptors including C-type lectin receptors and some TLRs [27,36–41]. Although the
relevance of these receptors in triggering bLF effects in human primary Mo and MoDCs is still poorly
known, it is of interest that major differences in the expression of at least some of these receptors
(e.g., CD14 and DC-SIGN) as well as in their involvement in specific LF effects have been reported
in Mo with respect to MoDCs. In this regard, we have previously demonstrated that CD14 and its
co-receptors TLR2 and TLR4, although not involved in bLF uptake by Mo, play a role in bLF-induced
signaling leading to IL-6 expression. Since CD14 is barely or not expressed at all at the surface of
MoDCs, and IL-6 is not induced by bLF in these cells, these results suggested that CD14 may represent
an important determinant for the differential effects induced by bLF in the two cell types. However,
the results achieved in this study rule out a possible involvement of CD14 in CCL1 induction, and
introduce an additional level of complexity. Although CCL1 induction is independent from CD14 and
TLR4, the differentiation stage influences, at least quantitatively, CCL1 expression, and relies on the
engagement of two different receptors, CD36 in Mo and TLR2 in MoDCs. Interestingly, receptors that
are engaged by LF to induce specific effects in myeloid immune cells, take part in receptor complexes
that play a crucial role in governing inflammation pathways such, as TLR4 [42] and TLR2 [43].
Likewise, CD36 facilitates TLR2 recognition and, together with CD14, is required for TLR2 response
to lipoteichoic acid [44–46]. On the basis of these observations and of our own results, we speculate
that LF effects may rely on receptor complexes, differently assembled depending on the cell type
and differentiation stage, that may positively or negatively interact to mediate LF-induced effects.
The apparent paradoxical effect of TLR2 blocking in Mo, up-modulating CCL1 secretion rather than
inhibiting as in MoDCs, can be likely explained by the complex interplay of several actors diversely
assembled/triggered by bLF at early and late differentiation stages.
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We have previously reported that bLF skews Mo differentiation into DCs with impaired capacity
to undergo activation and to promote Th1 responses, likely representing a strategy to block excessive
DC activation upon TLR-induced inflammation [26]. However, our attempts to link CCL1 to the
generation of DCs with distinct properties have failed (data not shown), and the precise role of this
chemokine in the bLF immunomodulatory effects still remains to be elucidated.
CCL1 plays a role not only in inflammation but also in apoptosis, angiogenesis and tumor
biology. Overall, the results of this study add further evidence for a critical role of bLF in directing
host immune function. As schematically depicted in Figure 4, Mo differentiating into DCs in
the presence of bLF acquire a tolerogenic phenotype and produce, throughout their differentiation
process, CCL1. We speculate that this chemokine may contribute to the anti-inflammatory activity of
bLF by recruiting CCR8+ cells (i.e., Treg and Th2 cells) and, by virtue of its protective effect against
apoptosis, to ensure the survival of the recruited cells, thus dampening inflammation.
Taken together, these findings shed some light on the mechanisms underlying bLF
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bLf preparations were  sterilized  by  filtration using  0.2  μm  filter  (Millipore Corp., Bedford, MA, 
USA) at low protein retention [47]. bLf contains a minimal amount of LPS, i.e., 0.7 EU/mg protein, 
corresponding  to 100 pg/mL  free LPS, by conventional Limulus Amebocyte Assay  (Charles River 
Endosafe, Charleston, SC, USA; detection  limit: 0.125 endotoxin units/mL). However, at  this LPS 
Figure 4. Schematic model of the proposed role of bLF-induced CCL1.
4. Experimental Section
4.1. Ethics Statements
Healthy donor buffy coats were obtained from Centro Trasfusionale, University of Rome
Sapienza. Buffy coats were not obtained specifically for this study. Informed consent has not been
asked because data were analyzed anonymously. Data from healthy donors have been treated by
Centro Trasfusionale according to the Italian law on personal data management, “Codice in materia
di protezione dei dati personali” (Testo Unico D.L., 30 June 2003, No. 196).
4.2. Reagents
Highly purified bLF in lyophilized form was kindly provided by Morinaga Milk Industries Co.,
Ltd., (Tokyo, Japan). bLf was checked for purity by Sodium Dodecyl Sulphate-Polyacrilamide Gel
Electrophoresis (SDS-PAGE) (Biorad, Segrate, Italy) and found to be contaminant-free, with a single
band displayed at 80 kDa upon staining with silver nitrate. The iron saturation of bLf was about
25%, as determined by optical spectroscopy (PerkinElmer, Monza, Italy). Before biological assays,
bLf preparations were sterilized by filtration using 0.2 µm filter (Millipore Corp., Bedford, MA,
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USA) at low protein retention [47]. bLf contains a minimal amount of LPS, i.e., 0.7 EU/mg protein,
corresponding to 100 pg/mL free LPS, by conventional Limulus Amebocyte Assay (Charles River
Endosafe, Charleston, SC, USA; detection limit: 0.125 endotoxin units/mL). However, at this LPS
concentration CCL1 secretion was not affected, and neither anti-TLR4 mAb influenced bLF capacity
to induce CCL1 secretion (data not shown and Figure 3). Recombinant human GM-CSF and IL-4
were a generous gift from Schering-Plough (Dardilly, France). Neutralizing monoclonal antibodies
(mAbs) against TLR4 (clone 15C1) [48] and TLR2 (clone T 2.5) [49] were kindly provided by Greg
Elson, anti-CD14 (clone 134620) and IgG1k isotype control Ab (clone 11711) were purchased from
R&D, anti-CD36 (clone FA6-152) was provided by GENETEX Inc. (Irvine, CA, USA) PE-conjugated
anti-CD14 (clone MφP9), anti-CD36 (clone CB38) and the corresponding isotype Ab were obtained
from BD Biosciences (Milan, Italy). PE-conjugated anti-TLR4 (clone HTA125), anti-TLR2 (T2.5) and
control Abs were from eBioscience.
4.3. Cell Isolation and Culture
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors buffy-coats
by Ficoll-Paque density centrifugation. CD14+ monocyte population was purified by positive
immunomagnetic bead selection (MACS monocyte isolation kit II from Miltenyi Biotec, Calderara
di Reno, Italy), according to the manufacturer’s instructions as previously described [50]. Freshly
isolated Mo were resuspended in RPMI 1640 medium Life Technologies, Monza, Italy) supplemented
with 2 mM L-glutamine, 2 mM penicillin/streptomycin and 10% fetalbovineserum (FBS) (Hyclone),
seededat 1 ˆ 106 cells/mL and treated with bLF in the presence of GM-CSF (50 ng/mL) and IL-4
(500 U/mL) to generate immature MoDCs [51]. GM-CSF and IL-4 were replenished at days 2 and 5
of culture. Cells were cultured at 37 ˝C, in a 5% CO2 and 95% H2O atmosphere.
4.4. CCL1 mRNA and Protein Detection
Total mRNA was extracted and processed for RT-PCR experiments as elsewhere indicated [52].
Validated PCR primers and TaqMan MGB probe (6FAM-labeled) for CCL1 were used (Hs00171072
m1; Applied Biosystems, Monza, Italy). As endogenous control, primers with TaqMan probe for
the human β actin were used (Hs99999903 m1; Applied Biosystems). CCL1 concentration was
measured by homemade ELISA, following the manufacturer’s instructions (sensitivity 15.6 pg/mL,
R&D System, Minneapolis, MN, USA).
4.5. Flow Cytometry
Cells were pre-incubated with PBS containing 10% human AB serum for 30 min on ice to block
unspecific Ig binding, then incubated with the specific or control Ab, respectively. After 30 min of
incubation on ice, cells were washed and fixed in 1% formaldehyde. Samples were acquired with a
FACS Calibur flow cytometer by using Cell Quest (Becton Dickinson, Milan, Italy) and data analyzed
by FlowJo software (Tree Star, Inc., Ashland, OR, USA).
4.6. Statistical Analysis
Statistical comparison between different experimental conditions was determined by the
Student’s t test (paired, two-tailed) by using SPSS and Graphpad software Inc. (La Jolla, CA, USA).
Where not specifically indicated by graph parenthesis, statistical significance was calculated with
respect to the untreated cells. When different treatments were performed, data were analyzed
by one-way ANOVA for repeated measures. The Tukey’s post-test was applied for multiple
comparisons. p values ď 0.05 were considered to reflect statistical significance; * p ď 0.05, ** p ď 0.01,
*** p ď 0.001.
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